ArticleCancers2020
Clinical, Genomic, and Pharmacological Study of
Open access · goldAbstract read
In one paragraph
Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 40 citations in OpenAlex.
- Definition of parameters and thresholds to detect MYCN amplification in retinoblastomas.Virchows Archiv : an international journal of pathology · 2026Article
- MYCN Amplification Drives Ferroptosis Susceptibility via Cysteine Metabolism in Retinoblastoma.Investigative ophthalmology & visual science · 2026Article
- High-throughput screening of drug libraries identifies a new synergistic drug combination for the treatment of retinoblastoma.PloS one · 2026Article
- Review
- Human Retinal Organoid Modeling Defines Developmental Window and Therapeutic Vulnerabilities in MYCN-Amplified Retinoblastoma.International journal of molecular sciences · 2025Article
- Update on Retinoblastoma Therapies.Medicina (Kaunas, Lithuania) · 2025Review
- Insights into retinoblastoma pathogenesis: unraveling RB1, N-MYC and miRNA profiles.BMJ open ophthalmology · 2025Article
- Tumor heterogeneity in retinoblastoma: a literature review.Cancer metastasis reviews · 2025Review
- Concurrent RB1 and P53 pathway disruption predisposes to the development of a primitive neuronal component in high-grade gliomas depending on MYC-driven EBF3 transcription.Acta neuropathologica · 2025Article
- Differentiating MYCN-amplified RB1 wild-type retinoblastoma from biallelic RB1 mutant retinoblastoma using MR-based radiomics: a retrospective multicenter case-control study.Scientific reports · 2024Article
- Ceftriaxone exerts antitumor effects in MYCN-driven retinoblastoma and neuroblastoma by targeting DDX3X for translation repression.Molecular oncology · 2024Article
- Review
- Correlating somatic copy number alteration in aqueous humour cfDNA with chemotherapy history, eye salvage and pathological features in retinoblastoma.The British journal of ophthalmology · 2024Article
- Correlation of gene expression with magnetic resonance imaging features of retinoblastoma: a multi-center radiogenomics validation study.European radiology · 2024Article
- Inhibition of high level E2F in a RB1 proficient MYCN overexpressing chicken retinoblastoma model normalizes neoplastic behaviour.Cellular oncology (Dordrecht, Netherlands) · 2024Article
- Establishment and Comprehensive Characterization of a Novel Preclinical Platform of Metastatic Retinoblastoma for Therapeutic Developments.Investigative ophthalmology & visual science · 2023Article
- Mutation spectrum of retinoblastoma patients in Vietnam.Molecular genetics & genomic medicine · 2023Article
- Translational screening platform to evaluate chemotherapy in combination with focal therapy for retinoblastoma.Cancer science · 2023Article
- MRI Features for IdentifyingRadiology · 2023Article
- Piperlongumine inhibits proliferation and oncogenic MYCN expression in chemoresistant metastatic retinoblastoma cells directly and through extracellular vesicles.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 6 institutions in 5 countries.
Santiago ZugbiPrecision Medicine, Hospital de Pediatría JP Garrahan, Buenos Aires 1245, Argentina.
Daiana GaniewichPrecision Medicine, Hospital de Pediatría JP Garrahan, Buenos Aires 1245, Argentina.
Arpita BhattacharyyaDepartment of Paediatric Haematology and Oncology, Tata Memorial Hospital, Kolkata 700160, India.
Rosario AscheroPrecision Medicine, Hospital de Pediatría JP Garrahan, Buenos Aires 1245, Argentina.ORCID 0000-0001-5971-3417
Daniela OttavianiInstitut Curie; PSL Research University, Centre National de la Recherche Scientifique (CNRS), UMR144, Equipe Ligue Contre le Cancer, 75005 Paris, France.
Claudia SamporHematology-Oncology Service, Hospital de Pediatría JP Garrahan, Buenos Aires 1245, Argentina.
Eduardo G CafferataNational Scientific and Technical Research Council, CONICET, Buenos Aires 1425, Argentina.
Marcela MenaPrecision Medicine, Hospital de Pediatría JP Garrahan, Buenos Aires 1245, Argentina.
Mariana SgroiOphthalmology Service, Hospital de Pediatría JP Garrahan, Buenos Aires 1245, Argentina.ORCID 0000-0003-2770-7009
Ursula WinterPathology Service, Hospital de Pediatría JP Garrahan, Buenos Aires 1245, Argentina.
Gabriela LamasPathology Service, Hospital de Pediatría JP Garrahan, Buenos Aires 1245, Argentina.
Mariona SuñolPathology Service, Hospital Sant Joan de Deu, 08950 Barcelona, Spain.
Manuel DaroquiCytogenetics Service, Hospital de Pediatría JP Garrahan, Buenos Aires 1245, Argentina.
Edgardo BaialardoCytogenetics Service, Hospital de Pediatría JP Garrahan, Buenos Aires 1245, Argentina.
Beatriz SalasPaediatric Oncology Service, Hospital Asencio Villaroel, Cochabamba 2500, Bolivia.
Anirban DasDepartment of Paediatric Haematology and Oncology, Tata Memorial Hospital, Kolkata 700160, India.ORCID 0000-0001-7653-9529
Adriana FandiñoOphthalmology Service, Hospital de Pediatría JP Garrahan, Buenos Aires 1245, Argentina.
Jasmine H FrancisOphthalmic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
Fabiana LubienieckiPathology Service, Hospital de Pediatría JP Garrahan, Buenos Aires 1245, Argentina.
Cinzia LavarinoPediatric Hematology and Oncology Service, Hospital Sant Joan de Deu, 08950 Barcelona, Spain.ORCID 0000-0002-9630-3676
Ralph GarippaGene editing and screening core facility, Department of Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0003-3917-0739
Osvaldo L PodhajcerNational Scientific and Technical Research Council, CONICET, Buenos Aires 1425, Argentina.ORCID 0000-0002-6512-8553
David H AbramsonOphthalmic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-0118-6391
François RadvanyiInstitut Curie; PSL Research University, Centre National de la Recherche Scientifique (CNRS), UMR144, Equipe Ligue Contre le Cancer, 75005 Paris, France.
Guillermo ChantadaPrecision Medicine, Hospital de Pediatría JP Garrahan, Buenos Aires 1245, Argentina.
Andrea S LleraNational Scientific and Technical Research Council, CONICET, Buenos Aires 1425, Argentina.ORCID 0000-0002-0089-0061
Paula SchaiquevichPrecision Medicine, Hospital de Pediatría JP Garrahan, Buenos Aires 1245, Argentina.ORCID 0000-0002-2568-4731
Garrahan Hospital · ARFundación Instituto Leloir · ARHospital Sant Joan de Déu Barcelona · ESMemorial Sloan Kettering Cancer Center · USCentre National de la Recherche Scientifique · FRTata Memorial Hospital · IN
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MAmazon Web Services 2018-2019Cancer Center Support Grant P30CA008748Fondation Nelia et Amadeo Barletta 2018Fondo para la Investigación Científica y Tecnológica PIDC 2014-0043Fundacion Garrahan 2019Fundacion Messi 2018Fundación Natalie Dafne Flexer de Ayuda al Niño con Cancer 2019Fund for Ophthalmic Knowledge, NY, US 2019Instituto 449 Oncologico Herny Moore 2018-2019Instituto Nacional del Cáncer 2015NCI NIH HHS P30 CA008748
Abstract
An uncommon subgroup of unilateral retinoblastomas with highly aggressive histological features, lacking aberrations in
Indexed as
metastatic retinoblastomaMYCN amplificationorbital disseminationwild-type RB1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.